A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

COPD is a group of progressive lung diseases that includes emphysema and chronic bronchitis. Despite affecting an estimated 32 million people in the United States, as many as half are unaware they ...

Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...